News | April 08, 2021
Zydus Cadila announces USFDA approval for Ibrutinib capsules
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
